

Cancer Enterprise UBS Conference Call Aug 31, 2017

Antoine Yver MD, MSc, EVP
Global Head of Oncology R&D and Chair of Cancer Enterprise

1. Cancer Enterprise Progress from June 2017

Key Data to be Presented and Significant Milestones:

- Key New Data
- Key New Studies Started
- Key New Strategic Collaborations

New Talent Joining CE – Capabilities

2. Highlights of DS-8201 Data from ASCO 2017

3. Q&A

DS CE New Data and Studies



Daiichi-Sankyo
cancerenterprise

Care. Compassion. Science.
It's Our Obligation.



- ✓ 6 Abstracts accepted
- ✓ Oral presentations on DS-8201 (and tivantinib)



- ✓ 4 Abstracts accepted ESMO
- ✓ Additional abstracts submitted to ASH and SABCS



- ✓ Breakthrough Therapy Designation by FDA for DS-8201 in HER2 breast cancer who have received trastuzumab, pertuzumab, and failed T-DM1

Key New Studies:

ClinicalTrials.gov

- ✓ DESTINY-Breast01: Pivotal Phase 2 HER2+ Breast Cancer study with DS-8201 (NCT03248492)
- ✓ U3-1402 in EGFRm NSCLC – (NCT03260491)
- ✓ First-time-to-man study in US DS-3201 (EZH1/2) in AML and ALL (NCT03110354)
- ✓ Combination study with DS-1205 (AXL) and Osimertinib in NSCLC (NCT03255083)

DS CE Key New Strategic Collaborations

DS CE: Key Strategic Collaborations Completed to date in 2017



Daiichi-Sankyo
cancerenterprise

Care. Compassion. Science.
It's Our Obligation.

* New Since we last met in June



Bristol-Myers Squibb

*Combination Study DS-8201 + nivolumab (Aug 2017)



*DS-5010 (RETi) out licensed to focus on our pipeline (Aug 2017)



*Progress re Bi-specific Antibody Collaboration (July 2017)



Max-Planck-Innovation

*Target discovery (July 2017)



THE UNIVERSITY OF TOKYO

*G47Δ (DS-1647) Oncolytic Virus Orphan Drug Designation in JP (July 2017)



KTE-C19 CAR T-cell (JPN Development, Jan 2017)

DS CE: Recent US-based Talent Acquisitions in 2017



Daiichi-Sankyo
cancerenterprise

Care. Compassion. Science.
It's Our Obligation.

New CE infrastructure & hires

ADC Task Force Team Leader – new hire
ADC Alliance Manager – JP Expat


CE R&D teams in NJ: New hires, leaders and individual contributors

Global Team Leader DS-8201
Global Clinical Leader DS-8201
Global Clinical Leader U3-1402
Global Head, Translational Development

New hires of Cross-functional leaders to enhance CE and work to meet our 2020 Business Goals

Global Head Oncology Marketing
Global Head Oncology Regulatory
Global Head Global Project Management Oncology
Global Head Oncology Clinical Operations
Global Head Oncology Medical Affairs
Chief of Staff Cancer Enterprise

DS-8201 (HER2 ADC) – Oral Presentation




Daiichi Sankyo CE at ASCO: Unique Identity




ADC: 7 Major Innovations as Introduced at ASCO

Daiichi Sankyo has delivered 7 major innovations on two critical components of ADC, payload and linker



Tumor size: best % change from baseline (5.4+6.4 mg/kg)



PRESENTED AT: ASCO ANNUAL MEETING '17 | #ASCO17

Slides are the property of the author. Permission required for reuse.



Presented by: Toshihiko Doi

Confirmed overall response rate (5.4+6.4 mg/kg)

	ORR n (%)	DCR n (%)
Total	39/97 (40.2)	89/97 (91.8)
Breast Cancer	19/45 (42.2)	44/45 (97.8)
BC Prior T-DM1	16/35 (45.7)	35/35 (100.0)
BC Prior T-DM1+Pertuzumab	14/30 (46.7)	30/30 (100.0)
Gastric Cancer	16/36 (44.4)	32/36 (88.9)
GC Prior CPT-11	8/18 (44.4)	17/18 (94.4)

Analysis set: Efficacy evaluable patients for confirmed overall response
Data cutoff on 11-May-2017

Tumor size: % Change from baseline (5.4 + 6.4 mg/kg)



Analysis set: Efficacy evaluable patients with at least one scan
Data cutoff on 11-May-2017

PRESENTED AT: ASCO ANNUAL MEETING '17 | #ASCO17

Slides are the property of the author. Permission required for reuse.

Presented by: Toshihiko Doi

TEAE, any grade, >20% (No DLT observed)

Preferred Term (N=133)	Grade 1 (%)	Grade 2 (%)	Grade 3 (%)	Grade 4 (%)	All (%)
Hematologic					
Platelet count decreased	13.5	9.0	8.3	3.8	34.6
Anemia	3.0	12.0	14.3	1.5	30.8
Neutrophil count decreased	0.8	9.8	12.0	3.0	25.6
White blood cell count decreased	0.8	12.8	9.0	1.5	24.1
Gastrointestinal disorders					
Nausea	51.9	13.5	1.5	0.0	66.9
Decreased appetite	33.8	20.3	3.8	0.0	57.9
Vomiting	31.6	3.8	1.5	0.0	36.8
Diarrhoea	19.5	5.3	0.8	0.0	25.6
Constipation	18.8	3.0	0.0	0.0	21.8
Others					
Alopecia	21.1	6.0	0.0	0.0	27.1
Malaise	18.0	4.5	0.8	0.0	24.1

Any Grade 3/4 – 43.6%

Analysis set: Safety evaluable patients who received at least one dose of DS-8201a
Data cutoff on 11-May-2017

Q&A



Daiichi-Sankyo
cancerenterprise